Transplantation of Allogeneic MSC in Patients With Pulp Necrosis and Chronic Apical Periodontitis
NCT ID: NCT04545307
Last Updated: 2020-09-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2/PHASE3
Total Enrollment
5 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-11-27
Study Completion Date
2020-01-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of the study is to evaluate the effect of Mesenchymal Stromal Cell (MSC) implantation on pulp and periapical regeneration of immature teeth with pulp necrosis and chronic apical periodontitis.
BACKGROUND:
* Post-traumatic pulp necrosis prevents root development in children and adolescents.
* The multipotent ability of MSC to differentiate into bone-forming cells (osteoblasts) and dentin-forming cells (Odontoblast) has allowed the development of protocols to induce dental pulp regeneration in preclinical models and patients with immature teeth with pulpal necrosis.
IMPACT:
* Worldwide, post-traumatic pulp necrosis in children and adolescents constitutes a health problem in the endodontic area.
* Treatment with MSC would provide an effective therapeutic alternative to patients with pulp necrosis and incomplete root formation.
* The possible pulp and periapical regeneration of immature teeth induced by MSC would have a huge impact on the treatment of these patients.
Eligibility for EMC implant study Age: 6 to 16 years Sex: Male or Female Healthy volunteers accepted: NO.
TREATMENT GROUPS:
In the present study, the implantation of MSC will be performed in patients with immature teeth with pulpal necrosis with apical periodontitis, who will receive the appropriate endodontic treatment (according to the guidelines of the American Association of Endodontics) and implantation of allogeneic BM-MSC . This group will be compared with the history made in the Postgraduate Endodontics of the Universidad Central de Venezuela (UCV) and with international case series made by revascularization.
Clinical follow-up of each patient:
1. Clinical controls (facial evaluation, gingival evaluation, apical palpation, horizontal and vertical percussion, cold and heat sensitivity tests) will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, a clinical evaluation will be carried out at the two years post-implantation of MSC.
2. Radiological controls will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, they will be carried out two years post-implantation of MSC.
3. A tomographic evaluation will be performed when was evident periapical repair in a periapical radiograph. To measure root formation, root canal narrowing and verification the periapical repair in 3D.
BACKGROUND:
* Post-traumatic pulp necrosis prevents root development in children and adolescents.
* The multipotent ability of MSC to differentiate into bone-forming cells (osteoblasts) and dentin-forming cells (Odontoblast) has allowed the development of protocols to induce dental pulp regeneration in preclinical models and patients with immature teeth with pulpal necrosis.
IMPACT:
* Worldwide, post-traumatic pulp necrosis in children and adolescents constitutes a health problem in the endodontic area.
* Treatment with MSC would provide an effective therapeutic alternative to patients with pulp necrosis and incomplete root formation.
* The possible pulp and periapical regeneration of immature teeth induced by MSC would have a huge impact on the treatment of these patients.
Eligibility for EMC implant study Age: 6 to 16 years Sex: Male or Female Healthy volunteers accepted: NO.
TREATMENT GROUPS:
In the present study, the implantation of MSC will be performed in patients with immature teeth with pulpal necrosis with apical periodontitis, who will receive the appropriate endodontic treatment (according to the guidelines of the American Association of Endodontics) and implantation of allogeneic BM-MSC . This group will be compared with the history made in the Postgraduate Endodontics of the Universidad Central de Venezuela (UCV) and with international case series made by revascularization.
Clinical follow-up of each patient:
1. Clinical controls (facial evaluation, gingival evaluation, apical palpation, horizontal and vertical percussion, cold and heat sensitivity tests) will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, a clinical evaluation will be carried out at the two years post-implantation of MSC.
2. Radiological controls will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, they will be carried out two years post-implantation of MSC.
3. A tomographic evaluation will be performed when was evident periapical repair in a periapical radiograph. To measure root formation, root canal narrowing and verification the periapical repair in 3D.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Autologous Alveolar Bone Marrow Mesenchymal Stem Cells for the Reconstruction of Infrabony Periodontal Defects
NCT02449005
Chronic Periodontitis
COMPLETED
PHASE1/PHASE2
Human Dental Pulp Mesenchymal Stem Cells for the Treatment of Chronic Periodontitis Patients
NCT05924373
Periodontitis
RECRUITING
PHASE2
Periodontal Regeneration of Chronic Periodontal Disease Patients Receiving Stem Cells Injection Therapy
NCT02523651
Periodontal Diseases
UNKNOWN
PHASE1/PHASE2
Progenitor Potential of Mesenchymal Stem Cells in Palatal Tissue Harvested From Molar and Premolar Sites
NCT03570333
Gingival Recession
Lack of Keratinized Gingiva (Disorder)
COMPLETED
NA
Osteoclast Impairment in Chronic Periodontitis by Regenerative Materials.
NCT03227367
Periodontal Disease
Periodontal Bone Loss
Osteoclastic Bone Loss
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The endodontic procedure in the patients included in this study will focus on cases of pulp necrosis with apical periodontitis without evidence of infectious processes.
MATERIALS AND METHODS. Reagents Murine monoclonal antibodies, directed against human differentiation antigens (CD34, CD45, CD14, CD90, CD73, CD29, CD49b, CD166), conjugated to fluorescein isothiocyanate (CFI) or phycoerythrin (PE) were purchased from BD Biosciences (USA).
Isolation and culture of mesenchymal stromal cells (MSC) obtained from human bone marrow. In the present study, isolated EMFs from bone marrow (BM) from patients with a diagnosis of post-traumatic nonunion (failure of a bone union at fracture sites) will be used. These cells were transplanted into the pseudoarthrosis site to induce bone regeneration in these patients. The protocol for bone regeneration through EMF transplantation was carried out at the University Hospital of Caracas, Hospital Universitario de Los Andes, Hospital Pérez de León II and has the approval of the Bioethics Committees of each institution and each patient through informed consent. In this protocol, the BM of each patient was isolated by a puncture in the iliac crest. This procedure was performed in the operating room, under anesthesia and by a medical specialist. The MO aspirate was placed in alpha-MEM medium (Invitrogen, USA) with heparin (Sanofi Aventis). The mononuclear cells were separated by centrifugation on a Ficoll-Hypaque gradient (GE Healthcare, Sweden) and cultured in alpha-MEM-Chang medium (Irvine Scientific, USA) enriched with 20% autologous serum. These cells were kept in culture in a controlled environment at 37ºC and 5% CO2. After 72 hours, non-adherent cells were eliminated, and a basal culture medium (alpha-MEM-Chang / 20% autologous serum) was added. Their adherence to the plastic isolated the MSCs. Culture medium exchanges were made until reaching a confluence close to 70-80%. The MSCs were expanded by pealing the cultures, following the process described above. Microbiological examinations were performed after obtaining the BM and before performing the MSC implantation. After using MSC, a batch of these cells were cryopreserved at -70 -C.
Phenotypic characterization of MSC. Phenotypic characterization studies of MSC were carried out by flow cytometry. For which the MO adherent cells were detached from the culture flask by using trypsin-like enzymes. Subsequently, the cells were incubated with antibodies specific for MSC markers (CD90, CD73, CD105, CD29, CD166 and CD49b) and hematopoietic (CD34, CD45 and CD14). Cytometric analysis of the expression markers showed that 100% of the cells used for transplantation in each patient were MSC.
MSC differentiation studies. The multipotential differentiation capacity of MSCs was examined by culturing these cells in osteogenic, chondrogenic and adipogenic differentiation media, following a methodology similar to that previously described. Briefly, the MSCs were detached and seeded in 24-well culture plates at a cell density of 5x104 per well, proceeding to add the corresponding differentiation medium. For osteogenic differentiation, MSCs were cultured in the presence of basal medium enriched with dexamethasone (100nM, Biotech), ascorbic acid (10mM, Sigma), inorganic phosphate (1.8mM, Merck) and beta-glycerol phosphate (2mM, Sigma). For chondrogenic differentiation, cells were cultured in a commercial medium for chondrocytes (Cell Application, USA) and for differentiation towards the adipogenic lineage the commercial medium NH Adipodiff Human (Miltenyi, USA) was used. In all cases, the cells were kept in culture for 21-28 days with medium changes every 4-5 days. To demonstrate the changes associated with the differentiation process, the cells were fixed using paraformaldehyde (Merck, USA) and specific stains were performed for each case. Briefly, alizarin red to detect calcium deposition (evidence of osteogenesis), Alcian blue to detect proteoglycans (evidence of chondrogenesis), and oil red (Oil Red) to see lipids (evidence of adipogenesis). In all cases, microscopic observation and photographic registration were carried out. For endothelial differentiation (CEn), EMFs were cultured in MCDB 131 medium (Invitrogen, USA) enriched with 10% autologous serum, 10µg / ml of human epidermal growth factor (hu-EGF, R\&D) and hydrocortisone (1µg / ml, Sigma).
MSC implantation in patients with pulp necrosis and apical periodontitis. All MSC processing procedures will be carried out in the cleanroom of the IVIC Cell Therapy Unit following the standards of good manufacturing practice (GMP). Allogeneic BM-MSC from patients diagnosed with post-traumatic nonunion and treated with implantation of these cells will be used to induce bone regeneration. The MSC to be used in this protocol have previously been phenotypically and functionally characterized. The MSC will be thawed, grown and expanded as previously described. A part of the cells will be kept in a medium for MSCs, and another part will be cultured in endothelial differentiation medium (CEM-Endo). Once the required number of MSCs and MSCs-Endo have been reached, a suspension of these cells (75,000 cells from each of them) will be placed in sterile culture tubes containing DMEM-F12 culture medium, without phenol red, supplemented with 20% autologous serum. Each tube containing MSC / MSC-Endo will be transported in a small biological sample transport cellar, at room temperature, to the Dentistry Service of the Instituto Venezolano de Investigaciones Científicas (IVIC).
Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the CEM / CEM-Endo "button (pellet)" is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the CEM / CEM-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth.
Post-implantation clinical evaluation of EMF
1. Clinical controls (facial evaluation, gingival evaluation, apical palpation, horizontal and vertical percussion, cold and heat sensitivity tests) will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, a clinical evaluation will be carried out at the two years post-implantation of EMC.
2. Radiological controls will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, they will be carried out two years post-implantation of mesenchymal stromal cells.
3. A tomographic evaluation will be performed when the periapical repair will be evident in a periapical radiograph.
MATERIALS AND METHODS. Reagents Murine monoclonal antibodies, directed against human differentiation antigens (CD34, CD45, CD14, CD90, CD73, CD29, CD49b, CD166), conjugated to fluorescein isothiocyanate (CFI) or phycoerythrin (PE) were purchased from BD Biosciences (USA).
Isolation and culture of mesenchymal stromal cells (MSC) obtained from human bone marrow. In the present study, isolated EMFs from bone marrow (BM) from patients with a diagnosis of post-traumatic nonunion (failure of a bone union at fracture sites) will be used. These cells were transplanted into the pseudoarthrosis site to induce bone regeneration in these patients. The protocol for bone regeneration through EMF transplantation was carried out at the University Hospital of Caracas, Hospital Universitario de Los Andes, Hospital Pérez de León II and has the approval of the Bioethics Committees of each institution and each patient through informed consent. In this protocol, the BM of each patient was isolated by a puncture in the iliac crest. This procedure was performed in the operating room, under anesthesia and by a medical specialist. The MO aspirate was placed in alpha-MEM medium (Invitrogen, USA) with heparin (Sanofi Aventis). The mononuclear cells were separated by centrifugation on a Ficoll-Hypaque gradient (GE Healthcare, Sweden) and cultured in alpha-MEM-Chang medium (Irvine Scientific, USA) enriched with 20% autologous serum. These cells were kept in culture in a controlled environment at 37ºC and 5% CO2. After 72 hours, non-adherent cells were eliminated, and a basal culture medium (alpha-MEM-Chang / 20% autologous serum) was added. Their adherence to the plastic isolated the MSCs. Culture medium exchanges were made until reaching a confluence close to 70-80%. The MSCs were expanded by pealing the cultures, following the process described above. Microbiological examinations were performed after obtaining the BM and before performing the MSC implantation. After using MSC, a batch of these cells were cryopreserved at -70 -C.
Phenotypic characterization of MSC. Phenotypic characterization studies of MSC were carried out by flow cytometry. For which the MO adherent cells were detached from the culture flask by using trypsin-like enzymes. Subsequently, the cells were incubated with antibodies specific for MSC markers (CD90, CD73, CD105, CD29, CD166 and CD49b) and hematopoietic (CD34, CD45 and CD14). Cytometric analysis of the expression markers showed that 100% of the cells used for transplantation in each patient were MSC.
MSC differentiation studies. The multipotential differentiation capacity of MSCs was examined by culturing these cells in osteogenic, chondrogenic and adipogenic differentiation media, following a methodology similar to that previously described. Briefly, the MSCs were detached and seeded in 24-well culture plates at a cell density of 5x104 per well, proceeding to add the corresponding differentiation medium. For osteogenic differentiation, MSCs were cultured in the presence of basal medium enriched with dexamethasone (100nM, Biotech), ascorbic acid (10mM, Sigma), inorganic phosphate (1.8mM, Merck) and beta-glycerol phosphate (2mM, Sigma). For chondrogenic differentiation, cells were cultured in a commercial medium for chondrocytes (Cell Application, USA) and for differentiation towards the adipogenic lineage the commercial medium NH Adipodiff Human (Miltenyi, USA) was used. In all cases, the cells were kept in culture for 21-28 days with medium changes every 4-5 days. To demonstrate the changes associated with the differentiation process, the cells were fixed using paraformaldehyde (Merck, USA) and specific stains were performed for each case. Briefly, alizarin red to detect calcium deposition (evidence of osteogenesis), Alcian blue to detect proteoglycans (evidence of chondrogenesis), and oil red (Oil Red) to see lipids (evidence of adipogenesis). In all cases, microscopic observation and photographic registration were carried out. For endothelial differentiation (CEn), EMFs were cultured in MCDB 131 medium (Invitrogen, USA) enriched with 10% autologous serum, 10µg / ml of human epidermal growth factor (hu-EGF, R\&D) and hydrocortisone (1µg / ml, Sigma).
MSC implantation in patients with pulp necrosis and apical periodontitis. All MSC processing procedures will be carried out in the cleanroom of the IVIC Cell Therapy Unit following the standards of good manufacturing practice (GMP). Allogeneic BM-MSC from patients diagnosed with post-traumatic nonunion and treated with implantation of these cells will be used to induce bone regeneration. The MSC to be used in this protocol have previously been phenotypically and functionally characterized. The MSC will be thawed, grown and expanded as previously described. A part of the cells will be kept in a medium for MSCs, and another part will be cultured in endothelial differentiation medium (CEM-Endo). Once the required number of MSCs and MSCs-Endo have been reached, a suspension of these cells (75,000 cells from each of them) will be placed in sterile culture tubes containing DMEM-F12 culture medium, without phenol red, supplemented with 20% autologous serum. Each tube containing MSC / MSC-Endo will be transported in a small biological sample transport cellar, at room temperature, to the Dentistry Service of the Instituto Venezolano de Investigaciones Científicas (IVIC).
Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the CEM / CEM-Endo "button (pellet)" is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the CEM / CEM-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth.
Post-implantation clinical evaluation of EMF
1. Clinical controls (facial evaluation, gingival evaluation, apical palpation, horizontal and vertical percussion, cold and heat sensitivity tests) will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, a clinical evaluation will be carried out at the two years post-implantation of EMC.
2. Radiological controls will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, they will be carried out two years post-implantation of mesenchymal stromal cells.
3. A tomographic evaluation will be performed when the periapical repair will be evident in a periapical radiograph.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pulp Necroses
Apical Periodontitis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
PRP clot loaded of BM-MSC in order to regenerate dental pulp tissue, placed in the root canal of an immature tooth from a patient with pulp necrosis and chronic apical periodontitis
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Allogenic transplant of BM-MSCs
Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo "button (pellet)" is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth.
Group Type
EXPERIMENTAL
Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis
Intervention Type
BIOLOGICAL
The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis
The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of pulp necrosis and apical periodontitis in teeth with immature apices.
* Informed consent by the patient's representative and consent by the patient to receive bone marrow allogeneic mesenchymal stromal cell transplantation treatment.
* Informed consent by the patient's representative and consent by the patient to receive bone marrow allogeneic mesenchymal stromal cell transplantation treatment.
Exclusion Criteria
* HIV positive
* Hepatitits B or C positive
* Autoimmune diseases: lupus, rheumatoid arthritis.
* Neoplastic diseases.
* Major metabolic disorders
* Pregnancy
* Being on steroid treatment
* Other criteria that the researchers consider inappropriate for the inclusion of the patient
* Hepatitits B or C positive
* Autoimmune diseases: lupus, rheumatoid arthritis.
* Neoplastic diseases.
* Major metabolic disorders
* Pregnancy
* Being on steroid treatment
* Other criteria that the researchers consider inappropriate for the inclusion of the patient
Minimum Eligible Age
6 Years
Maximum Eligible Age
16 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Venezolano de Investigaciones Cientificas
OTHER
Sponsor Role
collaborator
Universidad Central de Venezuela
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jose Francisco Gomez-Sosa
DDS, PhD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unidad de Terapia Celular del Instituto de Investigaciones Científicas
San Antonio de Los Altos, Miranda, Venezuela
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Venezuela
References
Explore related publications, articles, or registry entries linked to this study.
Antunes LS, Salles AG, Gomes CC, Andrade TB, Delmindo MP, Antunes LA. The effectiveness of pulp revascularization in root formation of necrotic immature permanent teeth: A systematic review. Acta Odontol Scand. 2016;74(3):161-9. doi: 10.3109/00016357.2015.1069394. Epub 2015 Jul 15.
Reference Type
BACKGROUND
Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006 Aug 1;98(5):1076-84. doi: 10.1002/jcb.20886.
Reference Type
BACKGROUND
Diaz-Solano D, Wittig O, Mota JD, Cardier JE. Isolation and Characterization of Multipotential Mesenchymal Stromal Cells from Congenital Pseudoarthrosis of the Tibia: Case Report. Anat Rec (Hoboken). 2015 Oct;298(10):1804-14. doi: 10.1002/ar.23198. Epub 2015 Jul 30.
Reference Type
BACKGROUND
Eramo S, Natali A, Pinna R, Milia E. Dental pulp regeneration via cell homing. Int Endod J. 2018 Apr;51(4):405-419. doi: 10.1111/iej.12868. Epub 2017 Nov 7.
Reference Type
BACKGROUND
Fouad AF. Microbiological aspects of traumatic injuries. Dent Traumatol. 2019 Dec;35(6):324-332. doi: 10.1111/edt.12494. Epub 2019 Oct 14.
Reference Type
BACKGROUND
Guerrero F, Mendoza A, Ribas D, Aspiazu K. Apexification: A systematic review. J Conserv Dent. 2018 Sep-Oct;21(5):462-465. doi: 10.4103/JCD.JCD_96_18.
Reference Type
BACKGROUND
Hawryluk GW, Mothe A, Wang J, Wang S, Tator C, Fehlings MG. An in vivo characterization of trophic factor production following neural precursor cell or bone marrow stromal cell transplantation for spinal cord injury. Stem Cells Dev. 2012 Aug 10;21(12):2222-38. doi: 10.1089/scd.2011.0596. Epub 2012 Feb 7.
Reference Type
BACKGROUND
Huang GT. Dental pulp and dentin tissue engineering and regeneration: advancement and challenge. Front Biosci (Elite Ed). 2011 Jan 1;3(2):788-800. doi: 10.2741/e286.
Reference Type
BACKGROUND
Iohara K, Nakashima M, Ito M, Ishikawa M, Nakasima A, Akamine A. Dentin regeneration by dental pulp stem cell therapy with recombinant human bone morphogenetic protein 2. J Dent Res. 2004 Aug;83(8):590-5. doi: 10.1177/154405910408300802.
Reference Type
BACKGROUND
Moradi S, Talati A, Forghani M, Jafarian AH, Naseri M, Shojaeian S. Immunohistological Evaluation of Revascularized Immature Permanent Necrotic Teeth Treated by Platelet-Rich Plasma: An Animal Investigation. Cell J. 2016 Fall;18(3):389-96. doi: 10.22074/cellj.2016.4567. Epub 2016 Aug 24.
Reference Type
BACKGROUND
Murakami M, Hayashi Y, Iohara K, Osako Y, Hirose Y, Nakashima M. Trophic Effects and Regenerative Potential of Mobilized Mesenchymal Stem Cells From Bone Marrow and Adipose Tissue as Alternative Cell Sources for Pulp/Dentin Regeneration. Cell Transplant. 2015;24(9):1753-65. doi: 10.3727/096368914X683502. Epub 2014 Jul 30.
Reference Type
BACKGROUND
Nakashima M, Iohara K. Regeneration of dental pulp by stem cells. Adv Dent Res. 2011 Jul;23(3):313-9. doi: 10.1177/0022034511405323.
Reference Type
BACKGROUND
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999 Apr 2;284(5411):143-7. doi: 10.1126/science.284.5411.143.
Reference Type
BACKGROUND
Shammaa R, El-Kadiry AE, Abusarah J, Rafei M. Mesenchymal Stem Cells Beyond Regenerative Medicine. Front Cell Dev Biol. 2020 Feb 18;8:72. doi: 10.3389/fcell.2020.00072. eCollection 2020.
Reference Type
BACKGROUND
Wang X, Thibodeau B, Trope M, Lin LM, Huang GT. Histologic characterization of regenerated tissues in canal space after the revitalization/revascularization procedure of immature dog teeth with apical periodontitis. J Endod. 2010 Jan;36(1):56-63. doi: 10.1016/j.joen.2009.09.039.
Reference Type
BACKGROUND
Wittig O, Diaz-Solano D, Cardier J. Viability and functionality of mesenchymal stromal cells loaded on collagen microspheres and incorporated into plasma clots for orthopaedic application: Effect of storage conditions. Injury. 2018 Jun;49(6):1052-1057. doi: 10.1016/j.injury.2018.04.005. Epub 2018 Apr 5.
Reference Type
BACKGROUND
Wittig O, Romano E, Gonzalez C, Diaz-Solano D, Marquez ME, Tovar P, Aoun R, Cardier JE. A method of treatment for nonunion after fractures using mesenchymal stromal cells loaded on collagen microspheres and incorporated into platelet-rich plasma clots. Int Orthop. 2016 May;40(5):1033-8. doi: 10.1007/s00264-016-3130-6. Epub 2016 Mar 16.
Reference Type
BACKGROUND
Xuan K, Li B, Guo H, Sun W, Kou X, He X, Zhang Y, Sun J, Liu A, Liao L, Liu S, Liu W, Hu C, Shi S, Jin Y. Deciduous autologous tooth stem cells regenerate dental pulp after implantation into injured teeth. Sci Transl Med. 2018 Aug 22;10(455):eaaf3227. doi: 10.1126/scitranslmed.aaf3227.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MSCYPPNAP001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Interleukin 8 And10 Levels Changes in Teeth with Necrotic Pulp and Apical Periodontitis
NCT06713174
NOT_YET_RECRUITING
NA
Regeneration of Immature Teeth. Case Series
NCT03507556
ACTIVE_NOT_RECRUITING
NA
Gingiva Mesenchymal Stem Cells Treatment of Chronic Periodontitis
NCT03137979
UNKNOWN
PHASE1/PHASE2
Serum TRAP-5b Levels in Patients With Generalized Chronic Periodontitis
NCT03043066
COMPLETED
NA
Enamel Matrix Proteins in the Treatment of Intrabony Defects in Patients With Aggressive and Chronic Periodontitis
NCT03025204
COMPLETED
PHASE4
Clinical Trials of Regeneration for Periodontal Tissue
NCT00221130
COMPLETED
PHASE1/PHASE2
The Safety and Tolerability of Initial Periodontal Therapy Combined With Human Dental Pulp Stem Cell Injection in the Treatment of Chronic Periodontitis
NCT04983225
UNKNOWN
PHASE1
Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction
NCT04446897
COMPLETED
PHASE1/PHASE2
Evaluation of Adipose Derived Stem Cells Exo.in Treatment of Periodontitis
NCT04270006
UNKNOWN
EARLY_PHASE1
Periodontal Ligament Stem Cell Implantation in the Treatment of Periodontitis
NCT01082822
UNKNOWN
PHASE1/PHASE2
Treatment of Intraosseous Periodontal Defects With Amelogenins
NCT05315804
RECRUITING
NA
Emdogain Minimally Invasive Surgical Technique
NCT02551770
COMPLETED
NA
Metronidazole and Amoxicillin for the Treatment of Type 2 Diabetic Subjects With Periodontitis
NCT02135952
UNKNOWN
PHASE4
Endocan, VEGF and TNF-alpha Levels in Periodontal Disease and After Treatment
NCT02750956
COMPLETED
The Impact of Obesity on Nonsurgical Periodontal Therapy
NCT01405365
UNKNOWN
NA
Metabolic Syndrome and Periodontitis
NCT02012842
UNKNOWN
NA
"Study of Halitosis in Patients With Advanced Chronic Periodontitis"
NCT02368678
COMPLETED
NA
STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER HIGH SENSITIVE C-REACTIVE PROTEIN. RANDOMIZED CONTROLLED CLINICAL TRIAL.
NCT01906450
UNKNOWN
NA
Locally Delivered Metformin and Aloe Vera for Treatment of Intrabody Defects in Chronic Periodontitis
NCT03204071
COMPLETED
PHASE2/PHASE3
Gingival Crevicular Fluid Vaspin and Omentin Levels in Type 2 Diabetic Patients With Chronic Periodontitis
NCT02544347
COMPLETED
NA
A Clinical Study of Connective Tissue Graft and Enamel Matrix Derivative in the Treatment of Intrabony Periodontal Defects
NCT07233733
COMPLETED
NA
A Clinical Trial Testing Root Coverage With Acellular Dermal Matrix in Thin and Thick Gingival Biotypes
NCT03057730
ACTIVE_NOT_RECRUITING
PHASE4
Impact of Non-surgical Periodontal Therapy on Oral and Gut Microbiome
NCT04580355
UNKNOWN
PHASE4
Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients
NCT01647282
COMPLETED
PHASE4
SCREENING OF EPIGENETIC BIOMARKERS (miRNAs) IN THE GINGIVAL SULCUS
NCT03510702
UNKNOWN